You are about to leave the ellacor site and be transferred to an independent medical portal.
The ellacor® System with Micro-Coring® Technology removes skin on the microscale.
Uniquely designed, ellacor provides optimal results with customization and simplicity in mind. A selection of sequences with varying skin removal percentages accommodates different patient needs, with pre-set specifications to elevate your technique.
Hall of Fame inventor known for transforming the industry with technologies, including Laser Hair Removal, Pulse Dye Laser, Fractional Laser, Coolsculpting.
Dr. William (Jay) Austen is recognized for composite tissue transplantation and development of numerous patents and prototypes of devices related to anti-aging, rejuvenation, and scar therapy.
“There’s nothing like it on the market. It’s a solid, effective product and a disruptive technology. Unlike an RF-based or ultrasound treatment, we actually remove skin, which is unlike microneedling. Its Micro-Coring treatment fits somewhere between energy-based skin rejuvenation and actual face-lift surgery.”
“Ideally a patient perhaps in her forties to sixties… just beginning to develop some jowls, marionette lines, some perioral lines, some of those fine lines in the lower cheeks. But they’re either not ready for surgery yet or they’re just unwilling to undergo surgery – that I see as the perfect candidate.”
“In my opinion, this new technology works very well for the beginning of skin laxity at the jowls, around the mouth and lower face. I am VERY enthusiastic about Micro-Coring with ellacor!”
“Patients want something with a surgical result, without having to go through the surgery. Ellacor is really the first technology to do this.”
“Because this is a mechanical device and not thermal like lasers or radiofrequency, it allows for rapid healing without scarring. And unlike microneedling, where skin is temporarily displaced, ellacor actually removes skin on the micro-scale and is the first device to do so.”
“ellacor takes advantage of the scientific concept of Micro-Coring which removes extremely tiny columns of tissue that heal without any visible scarring.”
“Prior to ellacor, there wasn’t a way of excising skin without leaving a visible scar… This breakthrough technology removes sagging skin on the microscale and provides trained clinicians with a unique solution for their patients.”
“In middle-aged patients, we’re going to use it to stave off a facelift. For women who have had a facelift and don’t want a second one, we’re going to be able to use it on them as well.”
“Deep layer facelifts do a good job with soft tissue repositioning in the midface. However, none of these surgeries do much for lines around the mouth in that area – that’s sort of the sweet spot for ellacor and I think my best results for perioral aging have come with a combination of ellacor…”
“So I think that, in terms of the skin, because it [ellacor] can remove it… I think that’s the final tool in the toolbox. There’s going to come a time in the not so distant future where it will be very rare for me to go into the OR for cosmetics.”
“The fact that you can actually offer patients a modality to have their skin removed by 7 or 8% from the treatment area without creating a scar… it creates substantial improvement.”
“ellacor is not like micro-needling, what you’re doing is taking small micro cores of skin…when you get the removal of that skin – it’s actually very smart – then the skin contracts.”
The ellacor® System with Micro-Coring® technology is indicated for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
Your medical professional will discuss the following side effects with you prior to treatment. Proper pre- and post-treatment care reduces the risk of these side effects; however, some conditions may or may not resolve over time. Side effects associated with this procedure may include: redness, swelling, bruising, burning, dryness, roughness, tightness/pulling of skin, crusting, pain/discomfort, tenderness, tingling, bleeding, numbness, skin peeling, or circular marks on skin.
Other side effects not commonly observed with this procedure may include: itching, hyper/hypo pigmentation, hematoma, infection, scarring, skin irregularities, skin necrosis, uneven appearance of the treated regions (left and right sides of face), or anesthesia toxicity (anesthesia-related complications may include allergic reaction and possibly death).
The ellacor® procedure should not be used for the treatment of areas of skin with dermatosis (e.g. skin tumors, keloids or in case of predisposition to keloids, solar keratosis, warts, or birthmarks), area within the bony orbital rim; mucous membranes; areas where silicone or synthetic material is implanted.
The ellacor® procedure should not be used on patients that are pregnant or nursing mothers, suffering from open wounds, sores, or irritated skin in the treatment area, have an allergy to stainless steel or allergy to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine. Patients that have a history or presence of any clinically significant bleeding disorder, have dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus should not be treated with the ellacor® procedure. Additionally, patients that have systemic infections or acute local skin infections such as Hepatitis disorders type A, B, C, D, E or F or HIV infection, take a high dose of anti-coagulants or blood-thinning substances (e.g. aspirin, nonsteroidal anti-inflammatory drugs, NSAIDs, warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days), are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area, have undergone plastic surgery of the face within the last twelve (12) months or have any facial surgical scars less than twelve (12) months old, have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive/invasive skin treatment in the treatment area during the previous six (6) months, or have scars less than six (6) months old in the treatment area should not be treated with the ellacor® procedure.
Appropriateness for treatment is based on the clinical assessment of the patient by the treating physician. Use caution when treating patients with the following conditions or taking the following medications: